Know Cancer

forgot password

A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma

Phase 3
18 Years
Not Enrolling
Renal Cell Carcinoma

Thank you

Trial Information

A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma

Primary Objective:

- The primary objective of this study is to determine whether subjects randomized to
receive adjuvant HSPPC-96 after surgical resection of locally advanced renal cell
carcinoma at high risk of recurrence, have improved recurrence-free survival as
compared to subjects with no adjuvant treatment.

Secondary Objective:

- Determine whether subjects randomized to receive HSPPC-96 have improved survival as
compared to subjects with no adjuvant treatment.

- Further characterize the safety profile of HSPPC-96.


Inclusion Criteria:

- Primary-intact resectable renal cell cancer, without known distant metastasis and be
scheduled to have surgery with curative intent;

- Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus
OR vena cava thrombus by radiologic evaluation

- Performance status (Zubrod / ECOG-WHO scale)less than or equal to 1 and life
expectancy of greater than three months, within 2 weeks of surgery.

- Women of child-bearing potential must have a negative urine or serum pregnancy test
within 2 weeks of surgery.

- Signed written informed consent.

Pre-Surgery Exclusion Criteria:

- Prior chemo-, hormonal, immuno- or radiotherapy for renal cell cancer;

- History of primary or secondary immunodeficiency, or patients using immunosuppressive
drugs, e.g. systemic corticosteroids, cyclosporin A;

- Current malignancies at other sites or previous other cancer within the last 5 years,
with the exception of adequately treated cone-biopsied in situ carcinoma of the
cervix uteri or basal or squamous cell carcinoma of the skin;

- Embolization of the renal artery prior to nephrectomy;

- Known distant metastases;

- Active, uncontrolled infection or other serious medical illnesses.

Eligibility Assessment:

(between 2 weeks pre- and 4 weeks post-surgery)

Prior to randomization and entry into the tumor evaluation phase, all subjects must
undergo testing to confirm that they are free of distant metastatic disease, and that they
meet all other criteria.

Eligibility Criteria which must be assessed and confirmed prior to randomization:

- No evidence of metastatic or residual renal carcinoma as documented by all of the
following: abdominal/pelvis CT scan; chest CT scan; and brain CT or MRI scan.

- Provide Antigenics with greater than or equal to 7 grams of viable tumor tissue

- Adequate bone marrow function.

- Adequate renal and hepatic function.

- Adequate cardiac function.

- Signed written informed consent.

- Patients must be willing to be followed during the course of tumor evaluation and
follow-up phases.

- Male or female patients of child producing potential must agree to use adequate
contraception during the treatment/observation phase of the study.

- Patients must not use any other investigational drug for four weeks prior to the
start of the tumor evaluation phase and throughout the tumor evaluation phase of the

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:

C-100-12 Part I



Start Date:

June 2000

Completion Date:

April 2007

Related Keywords:

  • Renal Cell Carcinoma
  • Kidney Cancer, renal, immunotherapy, tumor,
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms



Hinsdale, Illinois  60521
New Britain, Connecticut  06052
Bettendorf, Iowa  52722
Alexandria, Minnesota  56308
Albany, Georgia  31701
Phoenix, Arizona  85012
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Seattle, Washington  98195
McLean, Virginia  22101
Kansas City, Kansas  66160
Albuquerque, New Mexico  87131-5636
Metairie, Louisiana  70006
Anchorage, Alaska  
Denver, Colorado  
Baltimore, Maryland  21287
Boston, Massachusetts  
Charlotte, North Carolina  
Eugene, Oregon  
South Burlington, Vermont  
Milwaukee, Wisconsin